$204 Million is the total value of Aisling Capital Management LP's 16 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $104,371,750 | +3.7% | 6,068,125 | 0.0% | 51.13% | +5.6% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $23,578,541 | +5.3% | 1,115,352 | 0.0% | 11.55% | +7.2% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $21,453,250 | -0.9% | 1,025,000 | 0.0% | 10.51% | +0.9% | |
| BMEA | Biomea Fusion Inc (BMEA) | $17,532,716 | -29.2% | 798,757 | 0.0% | 8.59% | -27.9% | |
| GLUE | Monte Rosa Therapeutics Inc (GLUE) | $10,085,467 | -12.1% | 1,472,331 | 0.0% | 4.94% | -10.5% | |
| RPHM | Reneo Pharmaceuticals Inc (RPHM) | $5,812,652 | +9.7% | 886,075 | 0.0% | 2.85% | +11.6% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $4,573,816 | +8.4% | 2,541,009 | 0.0% | 2.24% | +10.4% | |
| ACRS | Aclaris Theraputics Inc (ACRS) | $4,505,298 | +28.2% | 434,455 | 0.0% | 2.21% | +30.5% | |
| ELEV | Elevation Oncology Inc (ELEV) | $4,309,063 | -20.0% | 2,834,910 | 0.0% | 2.11% | -18.6% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $2,591,849 | -2.7% | 1,205,511 | 0.0% | 1.27% | -0.9% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $1,836,150 | -42.9% | 1,043,267 | 0.0% | 0.90% | -41.8% | |
| AVRO | Avrobio, Inc. (AVRO) | $959,391 | -5.0% | 1,009,779 | 0.0% | 0.47% | -3.3% | |
| AGLE | Aeglea Biotherapeutics Inc (AGLE) | $761,864 | +55.3% | 1,691,151 | 0.0% | 0.37% | +58.1% | |
| VIRX | Viracta Therapeutics Inc (VIRX) | $406,885 | -11.3% | 288,571 | 0.0% | 0.20% | -10.0% | |
| BCEL | Atreca Inc. (BCEL) | $379,900 | -14.0% | 387,653 | 0.0% | 0.19% | -12.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.